

Edgar Filing: ANTIGENICS INC /DE/ - Form SC 13G/A

ANTIGENICS INC /DE/
Form SC 13G/A
May 12, 2008

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2

(Amendment No. 1)

Antigenics Inc.

(Name of Issuer)

Common Stock, par value \$0.01 per share

(Title of Class of Securities)

037032109

(CUSIP Number)

May 10, 2008

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1

CUSIP No. 037032109

1 NAME OF REPORTING PERSONS

Edgar Filing: ANTIGENICS INC /DE/ - Form SC 13G/A

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Invus Public Equities, L.P.
98-0420215

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)
(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Bermuda

	5	SOLE VOTING POWER	
			0
NUMBER OF	6	SHARED VOTING POWER	
SHARES			
BENEFICIALLY		6,866,666	
OWNED BY			
EACH	7	SOLE DISPOSITIVE POWER	
REPORTING			
PERSON			0
WITH:			
	8	SHARED DISPOSITIVE POWER	
			6,866,666

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,866,666 (includes 3,533,333 shares of Common Stock and 3,333,333 shares of Common Stock issuable upon exercise of warrants)

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.46%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

2

CUSIP No. 037032109

1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Invus Public Equities Advisors, L.L.C.

Edgar Filing: ANTIGENICS INC /DE/ - Form SC 13G/A

98-0420201

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)
(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER
0

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 6 SHARED VOTING POWER
6,866,666

7 SOLE DISPOSITIVE POWER
0

8 SHARED DISPOSITIVE POWER
6,866,666

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,866,666 (includes 3,533,333 shares of Common Stock and 3,333,333 shares of Common Stock issuable upon exercise of warrants)

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.46%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

3

CUSIP No. 037032109

1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Ulys, L.L.C.
83-0359139

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

Edgar Filing: ANTIGENICS INC /DE/ - Form SC 13G/A

(a)
(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER

0

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:

6 SHARED VOTING POWER

6,866,666

7 SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER

6,866,666

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,866,666 (includes 3,533,333 shares of Common Stock and 3,333,333 shares of Common Stock issuable upon exercise of warrants)

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.46%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

4

CUSIP No. 037032109

1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Raymond Debbane

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a)
(b)

Edgar Filing: ANTIGENICS INC /DE/ - Form SC 13G/A

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Panama

	5	SOLE VOTING POWER	
			0
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	6	SHARED VOTING POWER	
			6,866,666
	7	SOLE DISPOSITIVE POWER	
			0
	8	SHARED DISPOSITIVE POWER	
			6,866,666

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,866,666 (includes 3,533,333 shares of Common Stock and 3,333,333 shares of Common Stock issuable upon exercise of warrants)

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.46%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN

5

Item 1(a). Name of Issuer:

Antigenics Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

162 Fifth Avenue, Suite 900
New York, New York 10010

Item 2(a). Name of Person Filing:

Invus Public Equities, L.P.
Invus Public Equities Advisors, L.L.C.
Ulys, L.L.C.
Raymond Debbane

Edgar Filing: ANTIGENICS INC /DE/ - Form SC 13G/A

Item 2(b). Address of Principal Business Office or, if None, Residence:

750 Lexington Avenue
30th Floor
New York, New York 10022

Item 2(c). Citizenship:

Invus Public Equities, L.P. is a limited partnership organized under the laws of Bermuda.

Invus Public Equities Advisors, L.L.C. is a limited liability company organized under the laws of the State of Delaware.

Ulys, L.L.C. is a limited liability company organized under the laws of the State of Delaware.

Raymond Debbane is a citizen of Panama.

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number:

037032109

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), 13d-2(b) or (c), Check Whether the Person Filing is a:

- (a) Broker or dealer registered under Section 15 of the Exchange Act.
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act.

6

- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) Investment company as defined under Section 8 of the Investment Company Act.
- (e) An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E).
- (f) An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F).
- (g) A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G).
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
- (j) Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

Not Applicable.

Item 4. Ownership:

Edgar Filing: ANTIGENICS INC /DE/ - Form SC 13G/A

(a) Amount beneficially owned: 6,866,666

The number of shares of Common Stock beneficially owned includes 3,333,333 shares of Common Stock issuable upon exercise of warrants which are exercisable within 60 days of this Amendment Number 1 to Schedule 13G.

(b) Percent of class: 11.46%

Percent of class is based on 56,587,550 outstanding shares of common stock, par value \$0.01 per share, as reported by the Issuer on its Form 10-K/A, as filed with the Securities and Exchange Commission on March 24, 2008.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: 6,866,666

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of:
6,866,666

(iv) Shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of a class of securities, check the following .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

7

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 12, 2008

INVUS PUBLIC EQUITIES, L.P.

By: Invus Public Equities Advisors, L.L.C.,
As General Partner

By: /s/ Raymond Debbane

Raymond Debbane, President

INVUS PUBLIC EQUITIES ADVISORS, L.L.C.

By: /s/ Raymond Debbane

Raymond Debbane, President

ULYS, L.L.C.

By: /s/ Raymond Debbane

Raymond Debbane, President

RAYMOND DEBBANE

By: /s/ Raymond Debbane

Raymond Debbane

EXHIBIT A

JOINT FILING AGREEMENT

JOINT FILING AGREEMENT, dated as of May 10, 2008, among INVUS PUBLIC EQUITIES, L.P., INVUS PUBLIC EQUITIES ADVISORS, L.L.C., ULYS, L.L.C., and RAYMOND DEBBANE (collectively, the "Joint Filers").

WHEREAS, pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the parties hereto desire to satisfy any filing obligation under Section 13(g) of the Exchange Act by a single joint filing;

NOW, THEREFORE, in consideration of the premises and the mutual covenants

Edgar Filing: ANTIGENICS INC /DE/ - Form SC 13G/A

herein contained, the Joint Filers hereby agree and represent as follows:

1. The Amendment No. 1 to Schedule 13G filed with respect to the Common Stock of Antigenics Inc. (to which this Joint Filing Agreement is an exhibit) is filed on behalf of each of the Joint Filers.

2. Each of the Joint Filers is individually eligible to use Schedule 13G for the filing of information therein.

3. Each of the Joint Filers on whose behalf such Amendment No. 1 to Schedule 13G is filed is responsible for the timely filing of Schedule 13G, this Amendment No. 1 to Schedule 13G and any further amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein, provided that each such person is not responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

[SIGNATURE PAGE FOLLOWS]

10

IN WITNESS WHEREOF, each of the undersigned has caused this Joint Filing Agreement to be duly executed and delivered as of the date first above written.

INVUS PUBLIC EQUITIES, L.P.

By: Invus Public Equities Advisors, L.L.C.,
As General Partner

By: /s/ Raymond Debbane

Raymond Debbane, President

INVUS PUBLIC EQUITIES ADVISORS, L.L.C.

By: /s/ Raymond Debbane

Raymond Debbane, President

ULYS, L.L.C.

By: /s/ Raymond Debbane

Raymond Debbane, President

RAYMOND DEBBANE

By: /s/ Raymond Debbane

Raymond Debbane

11